March 8, 2022 – Melbourne, FL – A study published in BMJ Open describes the Patient Journey as it relates to awareness, communication, and involvement with decision making during experiences with preeclampsia, a potentially life-threatening hypertensive disorder of pregnancy. Preeclampsia is a hypertensive disorder of pregnancy that can affect many organs and occur in about 5% of all pregnancies and is a leading cause of maternal and infant illness and death worldwide. (See our Illustrated Patient Journey here.)
“This study presented a unique opportunity to ‘map’ how patients who are diagnosed with preeclampsia move through the experience of diagnosis, management, treatment, and postpartum physical and mental recovery,” said Preeclampsia Foundation CEO and study co-author Eleni Tsigas. “The study aimed to identify common pain points across the shared patient experience that could then be used by healthcare providers to improve outcomes.”
Preeclampsia Registry participants were asked to respond to a survey to measure their awareness of preeclampsia and symptoms, timing, and type of information on preeclampsia received, involvement in decision making regarding medical care, mental/emotional impact of the preeclampsia-complicated pregnancy and impact on future pregnancy planning.
“As clinicians, we see medical conditions through our own lens,” said senior author Ellen Seely, MD, the director of clinical research in the Division of Endocrinology, Diabetes and Hypertension at the Brigham and Women’s Hospital and professor at Harvard Medical School. “We were interested in having women tell us about their experience. When you want to understand how a disease affects the patient, you have to ask the patient.”
Based on responses from 833 women surveyed within the Preeclampsia Registry, researchers found:
Seely notes that counseling women about long-term risk is important because it gives them the opportunity to take preventive steps.
One known limitation of the study is that the Preeclampsia Registry is a study population that is predominantly non-Hispanic white and highly educated. In future studies, the researchers would like to include a more diverse population.
“In the future, this study should be replicated in a more diverse population,” said Seely. “One of our goals is to make these results known to clinical providers and public health organizations. We hope that by providing the patient perspective on the preeclampsia experience, we can educate providers to improve care.”
For more information about preeclampsia, the Preeclampsia Registry, and research in this field visit www.preeclampsia.org/research
About the Preeclampsia Foundation
The Preeclampsia Foundation is a U.S.-based 501(c)(3) non-profit organization established in 2000 to improve the outcomes of hypertensive disorders of pregnancy by educating, supporting, and engaging the community, improving healthcare practices, and finding a cure. We envision a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies. For more information, visit www.preeclampsia.org.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
The Preeclampsia Foundation's published research results.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...